Effect of Granulocyte-Colony Stimulating Factor on Endothelial Cells and Osteoblasts

published_or_final_versio

Effect of Ovariectomy on Stimulating Intracortical Remodeling in Rats

published_or_final_versio

Strontium incorporated coralline hydroxyapatite for engineering bone

Goniopora was hydrothermally converted to coralline hydroxyapatite (CHA) and incorporated with Sr (Sr-CHA). The pore size of Goniopora was in the range of 40–300 μm with a porosity of about 68%. Surface morphologies of the coral were modified to flake-like hydroxyapatite structures on CHA and the addition of Sr detected on Sr-CHA as confirmed by SEM and EDX. As the first report of incorporating Sr into coral, about 6%–14% Sr was detected on Sr-CHA. The compressive strengths of CHA and Sr-CHA were not compromised due to the hydrothermal treatments. Sr-CHA was studied in vitro using MC3T3-E1 cells and in vivo with an ovariectomized rat model. The proliferation of MC3T3-E1 cells was significantly promoted by Sr-CHA as compared to CHA. Moreover, higher scaffold volume retention (+40%) was reported on the micro-CT analysis of the Sr-CHA scaffold. The results suggest that the incorporation of Sr in CHA can further enhance the osteoconductivity and osteoinductivity of corals. Strontium has been suggested to stimulate bone growth and inhibit bone resorption. In this study, we have successfully incorporated Sr into CHA with the natural porous structure remained and explored the idea of Sr-CHA as a potential scaffolding material for bone regeneration.published_or_final_versio

BMP2 gene delivery to bone mesenchymal stem cell by chitosan-g-PEI nonviral vector

published_or_final_versio

Improved corrosion resistance of plasma carbon coated NiTi orthopedic materials

Nickel titanium (NiTi) alloys are useful in orthopedic applications because of their super-elastic properties and shape memory effects. However, when NiTi is used for a prolonged period of time, harmful Ni ions can leach out into the surrounding body fluid inside a human body, and so it is important to design a method to impede the out-diffusion of nickel from the materials into the biological medium. We aim at producing a barrier to mitigate the release of Ni ions during normal use. Carbon coatings have been shown to possess excellent bio-compatibility and good mechanical strength. In this work, amorphous hydrogenated DLC films with a graded C/NiTi interface were fabricated by plasma immersion ion implantation & deposition (PU & D) to provide such a barrier layer on NiTi. The elemental depth profiles and film thickness were determined by X-ray photoelectron spectroscopy (XPS) whereas the surface morphology was evaluated using atomic force microscopy (AFM). The film structure was studied by X-ray diffraction (XRD) and Raman spectroscopy. The corrosion resistance of the film was investigated using electrochemical tests based on ASTM G5-94. Compared to the control sample, the corrosion potential of the sample with the carbon coating changes from -250 to -50 mV and the film breakdown potential increases from 250 to 1200 mV. The corrosion current also diminishes from 10-6 to 10-7 A. The simulated body fluid (SBF) solutions after the electrochemical test were analyzed for Ni concentrations by inductively-coupled plasma mass spectrometry (ICPMS) and that data show that a much smaller amount of Ni has been released from the treated sample surface compared to the untreated control sample surface. Our results thus indicate that the deposited DLC film is effective in retarding the release of Ni ions from the bulk materials and more superior corrosion resistance is achieved based on our tests in a simulated fluid medium and at human body temperature.published_or_final_versio

Knowledge Author: Facilitating user-driven, Domain content development to support clinical information extraction

Background: Clinical Natural Language Processing (NLP) systems require a semantic schema comprised of domain-specific concepts, their lexical variants, and associated modifiers to accurately extract information from clinical texts. An NLP system leverages this schema to structure concepts and extract meaning from the free texts. In the clinical domain, creating a semantic schema typically requires input from both a domain expert, such as a clinician, and an NLP expert who will represent clinical concepts created from the clinician's domain expertise into a computable format usable by an NLP system. The goal of this work is to develop a web-based tool, Knowledge Author, that bridges the gap between the clinical domain expert and the NLP system development by facilitating the development of domain content represented in a semantic schema for extracting information from clinical free-text. Results: Knowledge Author is a web-based, recommendation system that supports users in developing domain content necessary for clinical NLP applications. Knowledge Author's schematic model leverages a set of semantic types derived from the Secondary Use Clinical Element Models and the Common Type System to allow the user to quickly create and modify domain-related concepts. Features such as collaborative development and providing domain content suggestions through the mapping of concepts to the Unified Medical Language System Metathesaurus database further supports the domain content creation process. Two proof of concept studies were performed to evaluate the system's performance. The first study evaluated Knowledge Author's flexibility to create a broad range of concepts. A dataset of 115 concepts was created of which 87 (76%) were able to be created using Knowledge Author. The second study evaluated the effectiveness of Knowledge Author's output in an NLP system by extracting concepts and associated modifiers representing a clinical element, carotid stenosis, from 34 clinical free-text radiology reports using Knowledge Author and an NLP system, pyConText. Knowledge Author's domain content produced high recall for concepts (targeted findings: 86%) and varied recall for modifiers (certainty: 91% sidedness: 80%, neurovascular anatomy: 46%). Conclusion: Knowledge Author can support clinical domain content development for information extraction by supporting semantic schema creation by domain experts

Nickel suppression in Ni-Ti alloys by plasma immersion ion implantation surface treatment: New materials for orthopaedic implantation

Conference Theme: Spinal Motion Segment: From Basic Science to Clinical Applicationpublished_or_final_versio

Enhanced gene delivery by chitosan-disulfide-conjugated LMW-PEI for facilitating osteogenic differentiation

postprin

The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice

A novel avian influenza virus H7N9 infection occurred among human populations since 2013. Although the lack of sustained human-to-human transmission limited the epidemics caused by H7N9, the late presentation of most patients and the emergence of neuraminidase-resistant strains made the development of novel antiviral strategy against H7N9 in urgent demands. In this study, we evaluated the potential of pamidronate, a pharmacological phosphoantigen that can specifically boost human Vδ2-T-cell, on treating H7N9 virus-infected humanized mice. Our results showed that intraperitoneal injection of pamidronate could potently decrease the morbidity and mortality of H7N9-infected mice through controlling both viral replication and inflammation in affected lungs. More importantly, pamidronate treatment starting from 3 days after infection could still significantly ameliorate the severity of diseases in infected mice and improve their survival chance, whereas orally oseltamivir treatment starting at the same time showed no therapeutic effects. As for the mechanisms underlying pamidronate-based therapy, our in vitro data demonstrated that its antiviral effects were partly mediated by IFN-γ secreted from human Vδ2-T cells. Meanwhile, human Vδ2-T cells could directly kill virus-infected host cells in a perforin-, granzyme B- and CD137-dependent manner. As pamidronate has been used for osteoporosis treatment for more than 20 years, pamidronate-based therapy represents for a safe and readily available option for clinical trials to treat H7N9 infection.published_or_final_versio

The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice

A novel avian influenza virus H7N9 infection occurred among human populations since 2013. Although the lack of sustained human-to-human transmission limited the epidemics caused by H7N9, the late presentation of most patients and the emergence of neuraminidase-resistant strains made the development of novel antiviral strategy against H7N9 in urgent demands. In this study, we evaluated the potential of pamidronate, a pharmacological phosphoantigen that can specifically boost human Vδ2-T-cell, on treating H7N9 virus-infected humanized mice. Our results showed that intraperitoneal injection of pamidronate could potently decrease the morbidity and mortality of H7N9-infected mice through controlling both viral replication and inflammation in affected lungs. More importantly, pamidronate treatment starting from 3 days after infection could still significantly ameliorate the severity of diseases in infected mice and improve their survival chance, whereas orally oseltamivir treatment starting at the same time showed no therapeutic effects. As for the mechanisms underlying pamidronate-based therapy, our in vitro data demonstrated that its antiviral effects were partly mediated by IFN-γ secreted from human Vδ2-T cells. Meanwhile, human Vδ2-T cells could directly kill virus-infected host cells in a perforin-, granzyme B- and CD137-dependent manner. As pamidronate has been used for osteoporosis treatment for more than 20 years, pamidronate-based therapy represents for a safe and readily available option for clinical trials to treat H7N9 infection.published_or_final_versio